Cape Verde vs Eswatini: Statin use vs. average non-HDL cholesterol levels
Cape Verde
2.8
in 2018
Eswatini
2.8
in 2018
Cape Verde rank
163rd
Eswatini rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Cape Verde
- Eswatini
How they compare
Cape Verde currently reports 2.8 against 2.8 in Eswatini, a difference of 0.
The two have swapped places 6 times across 39 shared years of data; in 1980 it was Eswatini ahead.
Cape Verde ranks 163rd and Eswatini ranks 163rd of 191 countries.
Cape Verde has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cape Verde | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.46 | 2.46 | 0 | — |
| 1990s | 2.67 | 2.58 | 0.09 | Cape Verde |
| 2000s | 2.76 | 2.69 | 0.07 | Cape Verde |
| 2010s | 2.8 | 2.77 | 0.0333 | Cape Verde |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Cape Verde or Eswatini?
- Cape Verde, at 2.8 against 2.8 in Eswatini as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Cape Verde and Eswatini?
- 0, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and Eswatini?
- 39 years are reported by both, from 1980 to 2018.
- How do Cape Verde and Eswatini rank globally for statin use vs. average non-hdl cholesterol levels?
- Cape Verde ranks 163rd and Eswatini ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.